Mefoxil 2 G/Vial

Cefoxitin sodium, the active ingredient in Mefoxil, is a second‑generation cephalosporin presented as a 2 g injectable solution (vial) for intravenous and intramuscular use. It treats a range of bacterial infections in adult and pediatric patients.

GNH USA supplies Mefoxil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cefoxitin sodium is a broad‑spectrum second‑generation cephalosporin used to treat infections caused by susceptible bacteria.

- Respiratory tract infections: effective for community‑acquired pneumonia and bronchitis. - Urinary tract infections: clears uncomplicated cystitis and pyelonephritis. - Intra‑abdominal infections: treats peritonitis and postoperative intra‑abdominal sepsis. - Gynecologic infections: manages pelvic inflammatory disease and postoperative uterine infections. - Skin and soft tissue infections: resolves cellulitis, abscesses and wound infections.

Adverse reactions may occur with any injectable antibiotic. Monitoring for both common and serious events is recommended.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the administration site. - Phlebitis: inflammation of the vein used for infusion. - Diarrhea: loose stools, often self‑limiting. - Nausea: transient feeling of queasiness. - Rash: mild erythematous skin eruption. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Clostridioides difficile‑associated diarrhea: severe colitis following antibiotic disruption of gut flora. - Stevens‑Johnson syndrome: rare mucocutaneous blistering disorder. - Hemolytic anemia: immune‑mediated destruction of red blood cells. - Renal impairment: acute kidney injury, especially in patients with pre‑existing dysfunction. - Seizures: rare neurotoxic effect, particularly with high doses or renal failure.

Cefoxitin sodium requires careful assessment before and during therapy.

- Allergy assessment: verify no history of severe penicillin or cephalosporin hypersensitivity. - Renal function monitoring: adjust dosage in patients with impaired kidney function. - Hepatic function evaluation: use caution in patients with liver disease. - Pregnancy considerations: category B, weigh maternal benefit against potential fetal risk. - Contraindication check: avoid in individuals with documented severe cephalosporin allergy. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Cefoxitin sodium can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent nephrotoxic agents (e.g., aminoglycosides): may increase risk of renal toxicity. - Probenecid: reduces renal clearance of cefoxitin, potentially raising serum levels. - Live bacterial vaccines: antibiotic may diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance nephrotoxic potential. - Oral contraceptives: possible reduction in contraceptive efficacy. - Warfarin: may cause unpredictable changes in INR, requiring closer monitoring.